STOCK TITAN
  1. Home
  2. News
  3. GILD

Gilead Sciences Inc - GILD STOCK NEWS

Welcome to our dedicated page for Gilead Sciences news (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.

Gilead Sciences, Inc. is an American biopharmaceutical company based in Foster City, California. The company specializes in researching, developing, and marketing antiviral drugs used in the treatment of a variety of viral infections including HIV/AIDS, hepatitis B and C, influenza, and COVID-19. Gilead is renowned for its innovative approach to creating life-saving therapies, with a core focus on diseases such as HIV and hepatitis. Some of its groundbreaking products include ledipasvir/sofosbuvir and sofosbuvir, pivotal in the treatment of hepatitis C.

Gilead's extensive portfolio has been significantly enhanced through strategic acquisitions. The purchase of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga has allowed the company to diversify into pulmonary and cardiovascular diseases and cancer treatments. The acquisition of Pharmasset was particularly notable, providing Gilead with the rights to the hepatitis C drug Sovaldi, further combined into the drug Harvoni. Additionally, Gilead has expanded its oncology offerings through the acquisitions of Kite, Forty Seven, and Immunomedics, strengthening its position in both cell therapy and non-cell therapy in oncology.

Gilead continually seeks to innovate and push the boundaries of medicine to offer better therapeutic solutions. Recent projects include expanding its antiviral pipeline and exploring novel treatments for various cancers. Financially, Gilead remains robust, with substantial investments in research and development to drive future growth and maintain its leadership in the biopharmaceutical industry.

News

Cognizant and Gilead Extend Partnership with Five-Year Service Agreement Estimated at $800 Million

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
partnership
-
News

New Biktarvy® Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic

Rhea-AI Summary
Gilead Sciences announced results from studies on Biktarvy as a treatment option for people with HIV. The studies included pregnant women, children, and adults with HIV/hepatitis B coinfection. In pregnant women, Biktarvy was well tolerated and maintained virologic suppression. In children, weight and lipid metabolism parameters improved with Biktarvy treatment. In adults with HIV/HBV coinfection, Biktarvy showed high rates of viral suppression and clinical benefits. Safety findings were similar between Biktarvy and other treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
none
-
News

Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities

Rhea-AI Summary
Gilead Sciences Inc. has announced its largest commitment to health equity for Indigenous communities in Australia and Canada. The company will establish a $6 million USD grant program to address the disparities in health outcomes impacting Indigenous communities, particularly in relation to HIV and viral hepatitis. The funding will be divided equally between the two countries and invested over three years, supporting frontline organizations and initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
none
News

Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS

Rhea-AI Summary
Gilead Sciences, Inc. (Nasdaq: GILD) announced the discontinuation of the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) due to futility. The safety data aligns with the known magrolimab profile. Gilead recommends discontinuing treatment with magrolimab in MDS patients. Magrolimab is a potential first-in-class, anti-CD47 immunotherapy with a clinical development program spanning ten potential indications. Gilead expressed disappointment but emphasized the importance of patient well-being and the challenges in treating HR-MDS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
clinical trial
-
News

Gilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
none
-
News

Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant From Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
none
News

Gilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023

Rhea-AI Summary
Gilead Sciences, Inc. (Nasdaq: GILD) announces contributions to the 12th International AIDS Society Conference on HIV Science (IAS 2023) in Brisbane, Australia. Updates on initiatives, collaborations, and new scientific data in HIV research and development will be shared. Gilead's focus on advancing HIV prevention, treatment, and cure strategies through partnerships and health equity efforts will be highlighted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
none
-
News

Gilead Sciences to Release Second Quarter 2023 Financial Results on Thursday, August 3, 2023

Rhea-AI Summary
Gilead Sciences, Inc. (Nasdaq: GILD) will release its second quarter 2023 financial results and guidance on August 3, 2023. The company's management will host a webcast to discuss the results and provide a business update. A live webcast will be available on the Investor Relations section of www.gilead.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
earnings
-
News

FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis

Rhea-AI Summary
Gilead Sciences, Inc. (Nasdaq: GILD) announced that the FDA approved Veklury as the first antiviral COVID-19 treatment for patients with severe renal impairment, including those on dialysis. The approval extends the use of Veklury to all stages of renal disease, addressing the increased risk of COVID-19 morbidity and mortality in patients with chronic kidney disease. This decision follows the European Commission's approval and is supported by Phase 1 and Phase 3 clinical trial results, demonstrating Veklury's safety and pharmacokinetics in this population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
fda approval covid-19
News

Gilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries

Rhea-AI Summary
GILD: Gilead Sciences Announces Partnerships to Accelerate Development of Pediatric HIV Medicines. The company is collaborating with CHAI and Penta ID Network to develop dispersible pediatric HIV medicines and bitter blockers for pediatric formulations. The partnership aims to address the high burden of mother-to-child transmission and low adherence rates among children.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
partnership

FAQ

What is the current stock price of Gilead Sciences (GILD)?

The current stock price of Gilead Sciences (GILD) is $90.19 as of November 22, 2024.

What is the market cap of Gilead Sciences (GILD)?

The market cap of Gilead Sciences (GILD) is approximately 111.8B.

What is Gilead Sciences, Inc.?

Gilead Sciences is an American biopharmaceutical company that focuses on developing antiviral drugs for diseases like HIV, hepatitis B and C, influenza, and COVID-19.

Where is Gilead Sciences headquartered?

Gilead Sciences is headquartered in Foster City, California.

What are some key products of Gilead Sciences?

Some key products include ledipasvir/sofosbuvir and sofosbuvir for hepatitis C treatment and several innovative antiviral therapies.

Which companies has Gilead Sciences acquired?

Gilead has acquired companies such as Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, Calistoga, Pharmasset, Kite, Forty Seven, and Immunomedics.

What diseases does Gilead Sciences' portfolio cover?

Gilead's portfolio covers life-threatening diseases like HIV, hepatitis B and C, pulmonary and cardiovascular diseases, influenza, and various cancers.

How has Gilead expanded its oncology offerings?

Gilead has bolstered its oncology portfolio through acquisitions of Kite, Forty Seven, and Immunomedics, enhancing its cell therapy and non-cell therapy options.

What is Gilead's financial condition?

Gilead maintains a strong financial position with significant investments in research and development to support ongoing growth and innovation.

What is Gilead's approach to research and development?

Gilead focuses on continual innovation and investment in R&D to develop groundbreaking treatments for viral infections and other serious diseases.

What recent projects is Gilead working on?

Gilead is currently working on expanding its antiviral drug pipeline and exploring new treatments for various types of cancer.

Where can I find the latest news about Gilead Sciences?

You can find the latest updates and news about Gilead Sciences on their official website and through reliable financial news sources.

Stock GILD logo
Gilead Sciences Inc

Nasdaq:GILD

GILD Rankings

#114 Ranked by Market Cap
#873 Ranked by Dividends

GILD Stock Data

111.79B
1.24B
0.12%
88.41%
1.42%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States of America
FOSTER CITY